First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

Journal Article

Full Text

Duke Authors

Cited Authors

  • Kapur, A; O’Connor-Semmes, R; Hussey, EK; Dobbins, RL; Tao, W; Hompesch, M; Smith, GA; Polli, JW; James Jr, CD; Mikoshiba, I; Nunez, DJ

Published Date

  • December 2013

Published In

Volume / Issue

  • 14 / 1

Electronic International Standard Serial Number (EISSN)

  • 2050-6511

Digital Object Identifier (DOI)

  • 10.1186/2050-6511-14-26